Corvel vs Starling Oncology
Corvel is the larger business, with $959m of revenue in fiscal 2026 against $503m for Starling Oncology (1.9 times as much). Starling Oncology grew faster (27.8% against 7.0%). Corvel kept more of each dollar of sales as profit: a net margin of 11.5% against -12.1%.
| Latest fiscal year | CorvelCRVL, 2026 | Starling OncologySTLN, 2025 |
|---|---|---|
| Revenue | $959m | $503m |
| Revenue growth | 7.0% | 27.8% |
| Net income | $110m | −$60.6m |
| Operating margin | — | — |
| Net margin | 11.5% | -12.1% |
| Return on equity | 30.8% | — |
| Free cash flow | $110m | −$27.8m |
| Cash | $233m | $33.6m |
| Total debt | $0 | $85.9m |
| Debt to equity | 0.0% | — |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | $56.2m | — |
| Employees | 5,239 | 641 |
| Market value | $4.20bn | $633m |
| Price vs our value range | — | — |
| Moat score | 68 (Moderate) | 12 (Weak) |
| Insider trades, 12 months | 0 buys, 26 sales | 16 buys, 11 sales |